BD (Becton, Dickinson and Company) announced the launch of the BD Surgiphor Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive… read more.
Guardant Health Inc. announced new data demonstrating that its Guardant Reveal blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months… read more.
Organon announced that it has entered into an agreement with Laborie Medical Technologies Corp., a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA… read more.
Chugai and Renalys Pharma, Inc. announced positive topline results from its Phase III clinical study of sparsentan (RE 021), an orally administered dual endothelin and angiotensin II receptor… read more.
GSK plc announced that the FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients… read more.
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used… read more.
GE HealthCare announced that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL… read more.
Kura Oncology, Inc. announced the first U.S. commercial sale of Komzifti (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa… read more.
Acadia Pharmaceuticals announced that the FDA has approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome… read more.
Axogen, Inc. announced that the FDA has approved the Biologics License Application (“BLA”) for Avance (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of… read more.
Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to… read more.
CSL announced five-year (60-month) results from the pivotal Phase III HOPE-B study, confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) in adults… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
